CTNNB1 and neoplasm: Tumours carrying CTNNB1 exon 3 mutations activate the Wnt/beta-catenin through aberrant translocation of beta-catenin from the membrane to the nucleus, where it can be identified using immunohistochemistry (IHC) [14].